Benzodiazepine use and risk of dementia: prospective population based study

Information sourced from BMJ:

BMJ 2012;345:e6231

[Free PDF | PubMed ® abstract]


Benzodiazepine use and risk of dementia: prospective population based study

Sophie Billioti de Gage, Bernard Begaud, Fabienne Bazin, et al

Correspondence to: or

Fig 3 Dementia-free survival in PAQUID study, in new benzodiazepine users and non-users at baseline


Objective To evaluate the association between use of benzodiazepines and incident dementia.

Design Prospective, population based study.

Setting PAQUID study, France.

Participants 1063 men and women (mean age 78.2 years) who were free of dementia and did not start taking benzodiazepines until at least the third year of follow-up.

Main outcome measures Incident dementia, confirmed by a neurologist.

Results During a 15 year follow-up, 253 incident cases of dementia were confirmed. New use of benzodiazepines was associated with an increased risk of dementia (multivariable adjusted hazard ratio 1.60, 95% confidence interval 1.08 to 2.38). Sensitivity analysis considering the existence of depressive symptoms showed a similar association (hazard ratio 1.62, 1.08 to 2.43). A secondary analysis pooled cohorts of participants who started benzodiazepines during follow-up and evaluated the association with incident dementia. The pooled hazard ratio across the five cohorts of new benzodiazepine users was 1.46 (1.10 to 1.94). Results of a complementary nested case-control study showed that ever use of benzodiazepines was associated with an approximately 50% increase in the risk of dementia (adjusted odds ratio 1.55, 1.24 to 1.95) compared with never users. The results were similar in past users (odds ratio 1.56, 1.23 to 1.98) and recent users (1.48, 0.83 to 2.63) but reached significance only for past users.

Conclusions In this prospective population based study, new use of benzodiazepines was associated with increased risk of dementia. The result was robust in pooled analyses across cohorts of new users of benzodiazepines throughout the study and in a complementary case-control study. Considering the extent to which benzodiazepines are prescribed and the number of potential adverse effects of this drug class in the general population, indiscriminate widespread use should be cautioned against.

© 2012 BMJ Publishing Group Ltd

The above message comes from BMJ, who is solely responsible for its content.

You have received this email because you requested follow-up information to an Epocrates DocAlert ® Message. For more information about DocAlert ® Messages, please click here.

Deja una respuesta

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *